MichaelYangWangMD

PubMed

• Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
  Zhang, L.,Yao, Y.,Zhang, S.,Liu, Y.,Guo, H.,Ahmed, M.,Bell, T.,Zhang, H.,Han, G.,Lorence, E.,Badillo, M.,Zhou, S.,Sun, Y.,Di Francesco, M. E.,Feng, N.,Haun, R.,Lan, R....> ;Sci Transl Med. 2019 May 10
• A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
  Strati, P.,Nastoupil, L. J.,Davis, R. E.,Fayad, L. E.,Fowler, N.,Hagemeister, F. B.,Kwak, L.,Oki, Y.,Wang, M.,Westin, J.,Ruben, C. E.,Wesson, E. T.,Piekarz, R.,Fanale,...> ;Haematologica. 2019 May 11
• Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
  Ahmed, M.,Lorence, E.,Wang, J.,Jung, D.,Zhang, L.,Nomie, K.,Wang, M.> ;Sci Signal. 2019 Feb 07
• 6 citations
  Whole mount histopathological correlation with prostate MRI in Grade I and II prostatectomy patients.
  Michael Wang, Nafiseh Janaki, Christina Buzzy, Laura Bukavina, Amr Mahran, Kirtishri Mishra, Gregory T. MacLennan, Lee Ponsky> ;International Urology and Nephrology. 2019 Jan 22
• Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
  Salles, G.,Gopal, A. K.,Minnema, M. C.,Wakamiya, K.,Feng, H.,Schecter, J. M.,Wang, M.> ;Clin Lymphoma Myeloma Leuk. 2019 Feb 24
• Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
  Li, C. J.,Jiang, C.,Liu, Y.,Bell, T.,Ma, W.,Ye, Y.,Huang, S.,Guo, H.,Zhang, H.,Wang, L.,Wang, J.,Nomie, K.,Zhang, L.,Wang, M.> ;Mol. Cancer Ther.. 2018 Nov 11
• Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
  Guo, H.,Zeng, D.,Zhang, H.,Bell, T.,Yao, J.,Liu, Y.,Huang, S.,Li, C. J.,Lorence, E.,Zhou, S.,Gong, T.,Jiang, C.,Ahmed, M.,Yao, Y.,Nomie, K. J.,Zhang, L.,Wang, M.> ;Oncogene. 2018 Oct 27
• Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
  L Jeffrey Medeiros, Jason R Westin, Michael Wang> ;Clinical Cancer Research.
• Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.
  Strati, P.,Fowler, N.,Pina-Oviedo, S.,Medeiros, L. J.,Overman, M. J.,Romaguera, J. E.,Nastoupil, L.,Wang, M.,Hagemeister, F. B.,Rodriguez, A.,Oki, Y.,Westin, J.,Turtur...> ;Clin Lymphoma Myeloma Leuk. 2017 Dec 03
• Current trials for frontline therapy of mantle cell lymphoma.
  Steiner, R. E.,Romaguera, J.,Wang, M.> ;J Hematol Oncol. 2018 Jan 29
• Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
  Felipe Samaniego, Jason Westin, Yasuhiro Oki, Pei Lin, Jorge E. Romaguera, Maria A. Rodriguez, Michael Wang, Lei Feng, Fredrick B. Hagemeister, Luis E. Fayad> ;The Oncologist. 2017 Apr 15
• B-cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
  Shaoying Li, Steven Y Huang, Michael Wang> ;Clinical Cancer Research. 2017 Mar 30
• Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
  Kuiatse, I.,Baladandayuthapani, V.,Lin, H. Y.,Thomas, S. K.,Bjorklund, C. C.,Weber, D. M.,Wang, M.,Shah, J. J.,Zhang, X.,Jones, R. J.,Ansell, S. M.,Yang, G.,Treon, S. ...> ;Clin. Cancer Res.. 2015 Mar 10
• Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.
  Hao, C.,Wang, L.,Peng, S.,Cao, M.,Li, H.,Hu, J.,Huang, X.,Liu, W.,Zhang, H.,Wu, S.,Pataer, A.,Heymach, J. V.,Eterovic, A. K.,Zhang, Q.,Shaw, K. R.,Chen, K.,Futreal, A....> ;Cancer Lett.. 2014 Dec 03
• Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
  Wang, M.,Fowler, N.,Wagner-Bartak, N.,Feng, L.,Romaguera, J.,Neelapu, S. S.,Hagemeister, F.,Fanale, M.,Oki, Y.,Pro, B.,Shah, J.,Thomas, S.,Younes, A.,Hosing, C.,Zhang,...> ;Leukemia. 2013 Apr 03
• Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
  Wang, M.,Fayad, L.,Wagner-Bartak, N.,Zhang, L.,Hagemeister, F.,Neelapu, S. S.,Samaniego, F.,McLaughlin, P.,Fanale, M.,Younes, A.,Cabanillas, F.,Fowler, N.,Newberry, K....> ;Lancet Oncol.. 2012 Jun 09
• 144 citations
  Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exp...
  Michael Wang, Meletios A. Dimopoulos, Christine Chen, M. Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zel...> ;Blood. 2008 Dec 1
• ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
  Ishizawa, J.,Kojima, K.,Chachad, D.,Ruvolo, P.,Ruvolo, V.,Jacamo, R. O.,Borthakur, G.,Mu, H.,Zeng, Z.,Tabe, Y.,Allen, J. E.,Wang, Z.,Ma, W.,Lee, H. C.,Orlowski, R.,Sar...> ;Sci Signal. 2016 Feb 18
• Join now to see all

Abstracts/Posters

• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
  Michael Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
  Michael Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Michael Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended ...
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Lan...
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma
  Michael Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• BI-1206, a Monoclonal Antibody Against Fc_riib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma
  Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Michael Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND ... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Dual Inhibition of PI3K Signaling and Histone Deacetylation Halts Proliferation and Induces Lethality in Mantle Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019